文献速递乳腺癌

SERENA-6扩展分析:一线治疗中ESR1突变出现时换用camizestrant

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-07-13

SERENA-6是一项双盲、安慰剂对照、随机3期试验,在激素受体阳性晚期乳腺癌一线芳香化酶抑制剂联合CDK4/6抑制剂治疗期间通过ctDNA监测ESR1突变,无影像学进展时随机换用camizestrant或继续原方案。

要点

  • ctDNA监测ESR1突变后换用camizestrant联合CDK4/6抑制剂显著改善PFS
  • 3-4级中性粒细胞减少在camizestrant组更常见(27% vs 17%)

核心结论

  • 一线治疗中ESR1突变出现时换用camizestrant联合CDK4/6抑制剂,相比继续芳香化酶抑制剂联合CDK4/6抑制剂,PFS获益持续并转化为PFS2统计学显著改善。

研究设计与样本

  • 双盲、安慰剂对照、随机3期试验,在23个国家264家医院和癌症中心开展。
  • 入组接受一线芳香化酶抑制剂联合CDK4/6抑制剂至少6个月的ER阳性、HER2阴性局部晚期或转移性乳腺癌患者(女性任何绝经状态或男性,≥18岁,ECOG PS 0-1)。
  • 共315例随机(camizestrant组157例,芳香化酶抑制剂组158例);主要终点为研究者评估的RECIST 1.1 PFS,关键次要终点为PFS2。

主要发现

  • 最常见的3-4级不良事件为中性粒细胞减少(camizestrant组42例[27%] vs 芳香化酶抑制剂组27例[17%])和中性粒细胞计数降低(35例[23%] vs 30例[19%])。
  • 严重不良事件发生在24例(15%) vs 29例(19%)患者;3例死亡被研究者认为可能与治疗相关。

关键数值与推荐

  • 3-4级中性粒细胞减少:42例(27%) vs 27例(17%);中性粒细胞计数降低:35例(23%) vs 30例(19%)。

临床怎么用

  • 支持在一线芳香化酶抑制剂联合CDK4/6抑制剂治疗期间通过ctDNA监测发现ESR1突变后,将内分泌治疗换为camizestrant并继续任何全球获批的CDK4/6抑制剂,以延长一线治疗获益。

局限性

  • 更新PFS分析为描述性分析。
  • PFS2的扫描评估间隔为8-12周。
  • 研究仍在进行中,总生存数据尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SERENA-6 is, to our knowledge, the first global registrational study to use prospective circulating tumour DNA (ctDNA) monitoring to identify the emergence of an acquired resistance mutation before clinical progression and then direct a change in therapy in patients with hormone receptor-positive advanced breast cancer. Switching to camizestrant from aromatase inhibitor with continued cyclin-dependent kinase (CDK) 4/6 inhibitor at ESR1 mutation emergence during first-line therapy significantly improved progression-free survival at interim analysis. We report comprehensive results from ESR1 mutation surveillance in SERENA-6, updated progression-free survival, final analysis of second progression-free survival with longer follow-up, and an exploratory analysis of ESR1 mutation ctDNA dynamics on treatment to give a comprehensive report of this new treatment strategy. METHODS: This double-blind, placebo-controlled, randomised, phase 3 trial was conducted at 264 hospitals and cancer centres in 23 countries and enrolled women with any menopausal status, or men, aged 18 years or older who were receiving first-line treatment with aromatase inhibitor plus CDK4/6 inhibitor for at least 6 months for oestrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer. Patients were required to have an Eastern Cooperative Oncology Group performance status score of 0 or 1. Eligible patients were enrolled and had ctDNA tested for ESR1 mutation every 2-3 months, coinciding with routine clinical assessments, using the Guardant360 CDx assay. Patients with an ESR1 mutation in ctDNA and without radiological progression were randomly assigned (1:1) using block randomisation (stratified by disease site, time of ESR1 mutation detection, time from initiation of aromatase inhibitor plus CDK4/6 inhibitor to randomisation, and CDK4/6 inhibitor) to switch to camizestrant (75 mg orally once daily) with continued CDK4/6 inhibitor (orally at the same dose) or to continue receiving aromatase inhibitor (anastrozole 1 mg or letrozole 2·5 mg orally once daily) plus CDK4/6 inhibitor (orally at the same dose as was received during ESR1 mutation surveillance phase). Palbociclib and ribociclib were dosed, orally, once daily for 21 days and then 7 days with no treatment in 28-day cycles, while abemaciclib was dosed, orally, twice daily every day in 28-day cycles. The SERENA-6 sample size was determined to ensure sufficient power for both the primary endpoint (investigator-assessed according to RECIST 1.1 progression-free survival) and the key secondary endpoint of investigator-assessed second progression-free survival (time from randomisation to disease progression after first subsequent therapy or death). For patients who had experienced a first progression, scans to assess second progression-free survival were conducted every 8-12 weeks. Updated progression-free survival analysis at this data cutoff was descriptive. Efficacy analyses included all randomly assigned patients (intention to treat). This study is registered with ClinicalTrials.gov, NCT04964934, and is ongoing. FINDINGS: From June 30, 2021, to June 14, 2024, 3325 patients were screened and 3256 patients received at least one ESR1 mutation test during first-line therapy and 548 patients had a positive ESR1 mutation test by the time of screening closure. 315 patients (312 [99%] female; 199 [63%] White, 73 [23%] Asian, six [2%] Black or African American, 37 [12%] other, not reported, or with missing race data) were randomly assigned: 157 to camizestrant plus CDK4/6 inhibitor and 158 to aromatase inhibitor plus CDK4/6 inhibitor. After a median follow-up of 23·5 months (IQR 17·9-32·1; data cutoff Jan 2, 2026), median progression-free survival was 16·8 months (95% CI 14·7-19·4) with camizestrant plus CDK4/6 inhibitor versus 9·2 months (7·2-9·7) with aromatase inhibitor plus CDK4/6 inhibitor (hazard ratio [HR] 0·45 [95% CI 0·34-0·59]; nominal p<0·0001); consistent with previous interim analysis. Median second progression-free survival was 25·7 months (95% CI 20·4-30·3) with camizestrant plus CDK4/6 inhibitor versus 19·1 months (16·8-21·0) with aromatase inhibitor plus CDK4/6 inhibitor; HR 0·63 (0·46-0·86; p=0·0037). The most common grade 3-4 adverse events were neutropenia (42 [27%] patients in the camizestrant plus CDK4/6 inhibitor group vs 27 [17%] patients in the aromatase inhibitor plus CDK4/6 inhibitor group) and neutrophil count decreased (35 [23%] vs 30 [19%] patients), while serious adverse events were reported in 24 (15%) versus 29 (19%) patients. There were three deaths considered by the trial investigator to be possibly related to treatment (camizestrant plus CDK4/6 inhibitor group: sudden death, possibly related to camizestrant; aromatase inhibitor plus CDK4/6 inhibitor group: sepsis, possibly related to abemaciclib, and ileus, possibly related to letrozole). INTERPRETATION: Switching to camizestrant plus CDK4/6 inhibitor at ESR1 mutation emergence, versus continuing aromatase inhibitor plus CDK4/6 inhibitor, resulted in sustained progression-free survival benefit that translated into a statistically significant improvement in second progression-free survival. These results further support switching endocrine treatment to camizestrant from aromatase inhibitor upon detection of ESR1 mutation, with continuation of any of the globally approved CDK4/6 inhibitor, to extend first-line treatment benefit. FUNDING: AstraZeneca.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Turner NC, Mayer EL, Park YH, et al. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026. PMID: 42442380. doi:10.1016/S1470-2045(26)00287-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。